Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.
More Turbulence Ahead: Polls On The US And EU In Europe
It will come as no surprise that views of the United States have plummeted in Europe and views of the European Union have ...